rivaroxaban and pyrazolanthrone

rivaroxaban has been researched along with pyrazolanthrone* in 1 studies

Other Studies

1 other study(ies) available for rivaroxaban and pyrazolanthrone

Article	Year
Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice. Scientific reports, 2019, 08-01, Volume: 9, Issue:1 Activated factor X (FXa) plays a central role in the coagulation cascade, while it also mediates vascular function through activation of protease-activated receptors (PARs). Here, we examined whether inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in streptozotocin (STZ)-induced diabetic mice. Induction of diabetes increased the expression of a major FXa receptor, PAR2, in the aorta (P < 0.05). Administration of rivaroxaban (10 mg/kg/day) to diabetic wild-type (WT) mice for 3 weeks attenuated endothelial dysfunction as determined by acetylcholine-dependent vasodilation compared with the control (P < 0.001), without alteration of blood glucose level. Rivaroxaban promoted eNOS Topics: Animals; Anthracenes; Aorta; Cell Line; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Factor Xa; Factor Xa Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Phosphorylation; Receptor, PAR-2; Rivaroxaban; Streptozocin; Vasodilation	2019

Article

Year

Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.

Scientific reports, 2019, 08-01, Volume: 9, Issue:1

Activated factor X (FXa) plays a central role in the coagulation cascade, while it also mediates vascular function through activation of protease-activated receptors (PARs). Here, we examined whether inhibition of FXa by rivaroxaban, a direct FXa inhibitor, attenuates endothelial dysfunction in streptozotocin (STZ)-induced diabetic mice. Induction of diabetes increased the expression of a major FXa receptor, PAR2, in the aorta (P < 0.05). Administration of rivaroxaban (10 mg/kg/day) to diabetic wild-type (WT) mice for 3 weeks attenuated endothelial dysfunction as determined by acetylcholine-dependent vasodilation compared with the control (P < 0.001), without alteration of blood glucose level. Rivaroxaban promoted eNOS

Topics: Animals; Anthracenes; Aorta; Cell Line; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelium, Vascular; Factor Xa; Factor Xa Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Phosphorylation; Receptor, PAR-2; Rivaroxaban; Streptozocin; Vasodilation

2019